13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001993440
Total reported value
$934.7M
$934.7M
33 檔
24.8%
During the Q4 2025 filing period, First Turn Management, LLC (CIK: 0001993440) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $934.7M across 33 reported positions.
First Turn Management, LLC executed strategic sector rebalancing during Q4 2025, establishing 12 new positions while fully exiting 8 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 5.87% | +1.18% | +30.64% | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.81% | +3.23% | -0.73% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 5.26% | -1.53% | -17.35% | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.20% | -0.72% | +0.97% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.35% | -1.40% | -15.60% | |
| 6 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.32% | +2.16% | +35.58% | |
| 7 | NUVL | Nuvalent Inc-a | Stock-Other | 4.24% | -3.89% | -6.60% | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.10% | -1.23% | — | |
| 9 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.10% | -2.86% | +17.88% | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.03% | -1.92% | EXIT | |
| 11 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.58% | +0.11% | +24.62% | |
| 12 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.54% | -2.02% | -25.48% | |
| 13 | VERA | Vera Therapeutics Inc | Stock-Other | 3.48% | -1.90% | EXIT | |
| 14 | COGT | Cogent Biosciences Inc | Stock-Other | 3.35% | -1.58% | — | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 3.21% | -1.95% | EXIT | |
| 16 | GH | Guardant Health Inc | Stock-Healthcare | 3.17% | — | — | |
| 17 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.94% | +1.36% | +23.66% | |
| 18 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.86% | -3.25% | EXIT | |
| 19 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.46% | +1.29% | — | |
| 20 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.45% | -1.93% | EXIT | |
| 21 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.36% | +2.72% | +27.82% | |
| 22 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.31% | -0.85% | — | |
| 23 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.23% | — | -40.01% | |
| 24 | NTRA | Natera Inc | Stock-Healthcare | 2.12% | -1.81% | EXIT | |
| 25 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.88% | -0.52% | -6.91% | |
| 26 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.84% | -1.11% | -25.67% | |
| 27 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.79% | +1.83% | NEW | |
| 28 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.76% | -1.28% | EXIT | |
| 29 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.54% | — | — | |
| 30 | IRON | Disc Medicine Inc | Stock-Other | 1.39% | — | -61.48% | |
| 31 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.20% | +1.46% | — | |
| 32 | QURE | uniQure N.V. | Stock-Other | 0.88% | +1.88% | — | |
| 33 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.40% | -0.66% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +2.2% | +30.64% | Add |
| 2 | VERA | Vera Therapeutics Inc | +1.9% | +69.74% | Add |
| 3 | APGE | Apogee Therapeutics Inc | +1.7% | +17.88% | Add |
| 4 | AXSM | Axsome Therapeutics Inc | +1.5% | +35.58% | Add |
| 5 | RVMD | Revolution Medicines Inc | +1.3% | -0.73% | Trim |
| 6 | ROIV | Roivant Sciences Ltd. | +0.8% | +23.66% | Add |
| 7 | BBIO | Bridgebio Pharma Inc | +0.6% | +0.97% | Add |
| 8 | NAMS | NewAmsterdam Pharma Company N.V. | +0.5% | +24.62% | Add |
| 9 | CYTK | Cytokinetics Inc | +0.3% | +27.82% | Add |
| 10 | NTRA | Natera Inc | +0.2% | — | Unchanged |
| 11 | MLTX | Moonlake Immunotherapeutics | +0.1% | — | Unchanged |
| 12 | KYMR | Kymera Therapeutics Inc | -0.5% | -25.67% | Trim |
| 13 | XENE | Xenon Pharmaceuticals Inc | -0.7% | — | Unchanged |
| 14 | NUVL | Nuvalent Inc-a | -0.9% | -6.60% | Trim |
| 15 | ASND | Ascendis Pharma A/S | -1.2% | -9.90% | Trim |
| 16 | INSM | Insmed Inc | -1.7% | -17.35% | Trim |
| 17 | UTHR | United Therapeutics CORP | -1.8% | -25.48% | Trim |
| 18 | MIRM | Mirum Pharmaceuticals Inc | -1.9% | -15.60% | Trim |
| 19 | ORIC | Oric Pharmaceuticals Inc | -2% | -6.91% | Trim |
| 20 | ARGX | Argenx Se - Adr | -2.1% | -40.01% | Trim |
| 21 | IRON | Disc Medicine Inc | -2.6% | -61.48% | Trim |
| 22 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 23 | ✓ | Merus N V | — | EXIT | Sold out |
| 24 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 25 | GH | Guardant Health Inc | — | NEW | New buy |
| 26 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 27 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 28 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
| 29 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 30 | FULC | Fulcrum Therapeutics Inc | — | NEW | New buy |
| 31 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 32 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 33 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 34 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 35 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 36 | OLMA | Olema Pharmaceuticals Inc | — | NEW | New buy |
| 37 | RCUS | Arcus Biosciences Inc | — | NEW | New buy |
| 38 | ADMA | Adma Biologics Inc | — | EXIT | Sold out |
| 39 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 40 | HROW | Harrow Inc | — | EXIT | Sold out |
| 41 | QURE | uniQure N.V. | — | NEW | New buy |
According to official SEC Form 13F filings, First Turn Management, LLC reported a total U.S. public equity portfolio value of $934.7M across 33 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, RVMD, INSM) accounted for 24.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
430
市值: $35.2M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $35.0M
During Q4 2025, First Turn Management, LLC's top holdings by market value included ABVX (5.9%)、RVMD (5.8%)、INSM (5.3%). The largest single position, ABVX, represented 5.9% of total portfolio value.
In Q4 2025, First Turn Management, LLC made 38 total portfolio adjustments, initiating 12 new buys, adding to 8 positions, trimming 10 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.